References
Braun J, Brandt J, Listing J, et al.: Treatment of active ankylosing spondylitis with infliximab:a randomized controlled multicenter trial. Lancet 2002, 359:1187–1193.
Van den Bosch F, Kruithof E, Baeten D, et al.: Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor-alpha (infliximab) versus placebo in spondyloarthropathy. Arthritis Rheum 2002, 46:755–765.
Kahn AK: Update on spondyloarthropathies. Ann Int Med 2002, 136:896–907.
Ralston SH, Hacking L, Willocks L, et al.: Clinical, biochemical and radiographic effects of aminohydroxypylidene bisphosphonate treatment in rheumatoid arthritis. Ann Rheum Dis 1989, 48:396–399.
Calin A, Nakache JP, Gueguen A, et al.: Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology 1999, 38:878–882.
Rights and permissions
About this article
Cite this article
Ritchlin, C.T. Intravenous pamidronate in treatment of nonsteroidal anti-inflammatory drug-refractory ankylosing spondylitis. Curr Rheumatol Rep 4, 498–499 (2002). https://doi.org/10.1007/s11926-002-0056-3
Issue Date:
DOI: https://doi.org/10.1007/s11926-002-0056-3